Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
8.80
+0.02 (0.23%)
At close: Apr 28, 2026, 4:00 PM EDT
8.80
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:15 PM EDT
Rallybio Employees
Rallybio had 14 employees as of December 31, 2025. The number of employees decreased by 11 or -44.00% compared to the previous year.
Employees
14
Change (1Y)
-11
Growth (1Y)
-44.00%
Revenue / Employee
$61,286
Profits / Employee
-$641,286
Market Cap
46.55M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14 | -11 | -44.00% |
| Dec 31, 2024 | 25 | -18 | -41.86% |
| Dec 31, 2023 | 43 | 2 | 4.88% |
| Dec 31, 2022 | 41 | 6 | 17.14% |
| Dec 31, 2021 | 35 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Xilio Therapeutics | 76 |
| Mereo BioPharma Group | 39 |
| Cue Biopharma | 29 |
| MiNK Therapeutics | 23 |
| Entera Bio | 22 |
| Atossa Therapeutics | 16 |
| Nutriband | 13 |
| Hyperion DeFi | 9 |
RLYB News
- 2 months ago - Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism - Benzinga
- 2 months ago - Rallybio Transcript: M&A announcement - Transcripts
- 2 months ago - Rallybio Corporation and Candid Therapeutics Announce Merger Agreement - Business Wire
- 2 months ago - Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 - Benzinga
- 2 months ago - Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement - Business Wire
- 3 months ago - Rallybio Announces Reverse Stock Split of Common Stock - Business Wire
- 3 months ago - Rallybio Transcript: EGM 2026 - Transcripts
- 6 months ago - Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire